Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease ...

Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Stocks were rising on Wednesday following the Federal Reserve’s decision to hold interest rates steady. The central bank ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

Board member Mick Hitchcock named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current role.REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...